BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $89 and keeps a Buy rating on the shares. Following the Q4 report, the firm updated for the current share count, which alters its per-share contributions, and increased revenue expectations for Casgevy in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics: Buy-Rated, Multi-Franchise Gene-Editing Platform with Strengthening CASGEVY Launch and Catalyst-Rich 2026 Outlook
- Maintaining a Hold: Casgevy Outperformance Balanced by Pipeline Execution Risks and Limited Valuation Upside
- Crispr Therapeutics: Buy Rating on Strengthening Casgevy Trajectory and High-Value In Vivo Gene-Editing Pipeline
- Crispr Therapeutics reports Q4 EPS ($1.37), consensus ($1.23)
- IBM, P&G, GameStop, Crispr, AGNC: Insider Moves Exposed